Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-301-7277
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.68 million
Profitability
Miscellaneous
Employees124
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions
What is Homology Medicines' stock symbol?
Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."
How were Homology Medicines' earnings last quarter?
Homology Medicines Inc (NASDAQ:FIXX) posted its earnings results on Thursday, August, 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The business earned $0.39 million during the quarter, compared to the consensus estimate of $1 million. Homology Medicines had a negative return on equity of 38.74% and a negative net margin of 3,232.67%. View Homology Medicines' Earnings History.
When is Homology Medicines' next earnings date?
What price target have analysts set for FIXX?
4 equities research analysts have issued 1 year price targets for Homology Medicines' shares. Their predictions range from $29.00 to $37.00. On average, they anticipate Homology Medicines' share price to reach $33.00 in the next year. This suggests a possible upside of 153.5% from the stock's current price. View Analyst Price Targets for Homology Medicines.
What is the consensus analysts' recommendation for Homology Medicines?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.
Has Homology Medicines been receiving favorable news coverage?
Headlines about FIXX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Homology Medicines.
Who are some of Homology Medicines' key competitors?
Some companies that are related to Homology Medicines include Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH) and Apellis Pharmaceuticals (APLS).
What other stocks do shareholders of Homology Medicines own?
Who are Homology Medicines' key executives?
Homology Medicines' management team includes the folowing people:
- Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
- Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
- Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
- Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
- Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)
When did Homology Medicines IPO?
(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Homology Medicines?
Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Homology Medicines' stock price today?
One share of FIXX stock can currently be purchased for approximately $13.02.
How big of a company is Homology Medicines?
Homology Medicines has a market capitalization of $572.49 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.
What is Homology Medicines' official website?
How can I contact Homology Medicines?
Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.
MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
